As this week's rallies approach, four tell how their concern for the environment has changed their lives and careers Chemical physicist Michael Oppenheimer remembers staring for hours at the poster in his bedroom. The vertical cliffs of granite that had once been Colorado's Glen Canyon shimmered down pink and orange from the wall of his Cambridge, Mass., apartment. Several years earlier, in 1967, a dam had been built and the canyon flooded, its beauty lost forever. "It blew me away," says the

An immunologist who has turned entrepreneur builds a one-man publishing business around a 30,000-item directory It is one of those small yet irksome inconveniences that dog immunologists and those working with biological reagents. No matter how generous one's funding or how proficient one's technicians, there are certain nettlesome tasks that threaten to halt one's research. What to do, for example, when an experiment requires a highly specific monoclonal antibody? If it can't be found in a ca

Report says biotech firms must pick up the slack to supplement federal funding of the next generation of scientists WASHINGTON -- Biotechnology companies are running out of scientists, and it may be up to industry itself to educate the next generation of biochemists, according to a new report from the National Research Council. The report, funded by the National Institutes of Health at the behest of Congress, recommends that federally supported traineeships and fellowships for biomedical grad

New DNA technology outpaces NIH committee's original charter as other agencies move to regulate experiments in genetics. WASHINGTON--A government panel that oversees scientific experiments involving genetically engineered organisms is grappling with an issue that could alter the way in which that science is performed. The National Institutes of Health's Recombinant DNA Advisory Committee (known as "the RAC"), was formed in 1974 after scientists recognized the need for guidelines to control the